Page last updated: 2024-08-22

indocyanine green and LCIS, Lobular Carcinoma In Situ

indocyanine green has been researched along with LCIS, Lobular Carcinoma In Situ in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Anderson, BO; Byrd, DR; Calhoun, KE; Dintzis, SM; Fortney, T; Gombotz, C; Hales, L; Hansen, S; Harrington, KM; Ishak, L; Javid, SH; Kittle, D; Miller, DM; Parrish-Novak, J; Perry, J; Porenta, S; Tan, LC1

Trials

1 trial(s) available for indocyanine green and LCIS, Lobular Carcinoma In Situ

ArticleYear
Real-time Visualization of Breast Carcinoma in Pathology Specimens From Patients Receiving Fluorescent Tumor-Marking Agent Tozuleristide.
    Archives of pathology & laboratory medicine, 2019, Volume: 143, Issue:9

    Topics: Breast Carcinoma In Situ; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Female; Fluorescent Dyes; Humans; Indocyanine Green; Intraoperative Care; Margins of Excision; Mastectomy; Mastectomy, Segmental; Neoplasm Invasiveness; Prognosis; Scorpion Venoms

2019